PCN96 US COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO...

Value in Health 2019 / 05 Vol. 22

PCN96 US COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO REGORAFENIB AND CABOZANTINIB IN SECOND LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA

Upadhyay, N., Mistry, R., Suri, G., Phelps, H., Guest, S., Muston, D.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.220
Date:
May, 2019
File:
PDF, 653 KB
english, 2019
Conversion to is in progress
Conversion to is failed